The Hyris System™ can detect SARS-CoV-2 despite all the novel variants - Update
As the new mutations of SARS-CoV-2 keep spreading world-wide, significant concerns increasingly worry both citizenship and the institutions. Even if some of these variants are innocuous, others may give the virus a selective advantage. Based on a risk assessment by major authorities involved in the fight against the spread of COVID-19, such as WHO, ECDC, CDC, these mutations are identified as Variants of Concern and monitored, alerting even more globally scientific and medical communities.
The updated list of the Variants of Concern emerged so far is:
- United Kingdom variant known as VOC 202012/01
- South Africa variant known as 501Y.V2
- Brazil variant known as 484 K.V2
- Indian variant known as B.1.617
- Californian variants known as B.1.429 and B.1.427
Hyris keeps monitoring the surveillance data and has performed routine in silico analysis of SARS-CoV-2 sequences (from GISAID database: https://www.gisaid.org/) in order to safeguard both public health and the quality of the product, by assessing their potential impact on inclusivity and performance characteristics. All sequences investigated showed no variations from the reference sequence of SARS-CoV-2 in the oligonucleotides annealing sites. These include all the Variants of Concern mentioned above.
All sequences investigated showed no variations from the reference sequence of SARS-CoV-2 in the oligonucleotides annealing sites. These include all the Variants of Concern mentioned above.
The Diagnostical Coverage of the Hyris System (bCUBE, bKITs, bAPP, bDATA) is currently 100% based on in silico analysis.
Download the complete Monitoring update HERE
Contact us to understand how we can help you perform beyond your current diagnostic capability boundaries throughout this critical time.